What the Wegovy and Zepbound labels say
The prescribing information warns that acute pancreatitis has occurred with GLP-1 treatment. While reviewing GLP-1 side effects, pay particular attention to persistent or severe abdominal pain, which can spread to the back and may occur with or without nausea or vomiting. If you develop symptoms suggestive of pancreatitis while taking Wegovy or Zepbound, stop the medication and seek medical care promptly, as directed in the product information.[3][5]
What recurrence studies found
A TriNetX study reviewed records for 258,238 people with type 2 diabetes or obesity and a history of acute pancreatitis. In the subgroup without other recorded risk factors, recurrence was recorded in 13.8% of GLP-1 users and 40.9% of nonusers. Prescribing was not randomized, and the percentages apply to that subgroup.[1]
A separate retrospective cohort of 46,186 people with diabetes and either prior pancreatitis or elevated lipase found a higher hazard of pancreatitis with GLP-1 use (adjusted hazard ratio 1.252, 95% confidence interval 1.178 to 1.332). Only 10,933 people entered the cohort because of prior pancreatitis. The two studies used different populations and methods and cannot establish how a specific patient would respond.[6]
What older randomized trials can tell us
A 2017 meta-analysis found no statistically significant difference in pancreatitis in type 2 diabetes trials (odds ratio 0.93, 95% confidence interval 0.65 to 1.34). Of 113 eligible trials, 13 did not report pancreatitis and 72 reported no cases in any arm. The review did not estimate recurrence in people selected for a history of pancreatitis and predates tirzepatide trials. Its findings on gallbladder problems covered a separate outcome, gallstones.[2]
How chronic pancreatitis differs
In a study of people with chronic pancreatitis and without diabetes, researchers matched 1,422 patients per group. In the recurrence analysis, acute pancreatitis was recorded in 19 of 799 GLP-1 users (2.4%) and 76 of 704 comparison patients (10.8%). Mean follow-up was about 459 and 664 days, respectively. The authors could not verify the chronic pancreatitis diagnosis from clinical testing and cautioned against using these results to guide prescribing.[4]
If you had pancreatitis before, share when it happened, its known cause, and whether you have had more than one episode. That history helps your prescriber weigh the treatment options and decide how to follow up.